Compass Therapeutics (CMPX) Cash from Financing Activities (2018 - 2026)

Compass Therapeutics has disclosed Cash from Financing Activities across 9 years of filings, most recently posting $3.4 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $3.4 million, up 512.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $133.8 million (up 14802.09% YoY), and the FY2025 annual result was $129.6 million, up 647.54% from the prior year.
• Cash from Financing Activities came in at $3.4 million for Q1 2026 at Compass Therapeutics, up from $1.1 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $129.4 million in Q3 2025 to a low of -$815000.0 in Q1 2025.
• The 5-year median for Cash from Financing Activities is $31000.0 (2023), against an average of $16.4 million.
• Across the five-year window, Cash from Financing Activities slumped 109.52% in 2024 and jumped 6468150.0% in 2025, its largest moves.
• Compass Therapeutics' Cash from Financing Activities stood at $75.8 million in 2022, then sank by 100.21% to -$158000.0 in 2023, then surged by 40.51% to -$94000.0 in 2024, then soared by 1230.85% to $1.1 million in 2025, then surged by 216.56% to $3.4 million in 2026.
• The last three Cash from Financing Activities figures came in at $3.4 million (Q1 2026), $1.1 million (Q4 2025), and $129.4 million (Q3 2025), per Business Quant data.